会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明公开
    • BEHÄLTERANORDNUNG FÜR FÜLLGUT
    • BEHÄLTERANORDNUNGFÜRFÜLLGUT
    • EP2931616A1
    • 2015-10-21
    • EP13821799.7
    • 2013-12-11
    • Corpack GmbH
    • CORBEIL, Jean Paul
    • B65D21/02B65D81/32
    • B65D25/38B65D11/20B65D21/0204B65D21/0231B65D21/0237B65D43/14B65D81/3205B65D81/3216
    • The invention relates to a container arrangement for filling material, comprising at least one first, independent container part having a closeable discharge opening, and a second independent container part having a closeable discharge opening. The second container part can be arranged in a removable manner in a recess of the first container part such that the first container part and the second container part can be connected to the container arrangement. The first discharge opening and the second discharge opening point in different directions. The first discharge opening can be closed by a first closure part and the second discharge opening can be closed by a second closure part. At least the second closure part overlaps a partial area of the second container part and locks a partial area of the first container part.
    • 用于产品的容器装置包括至少一个具有可关闭分配开口的第一独立容器部分和具有可关闭分配开口的第二独立容器部分。 第二容器部分可以可拆卸地布置在第一容器部分的凹部中,使得第一容器部分和第二容器部分连接以形成容器装置,其中第一分配开口和第二分配开口点在 不同的方向 第一分配开口可以由第一闭合部分闭合,并且第二分配开口可以被第二闭合部分封闭。 至少第二封闭部分以锁定方式与第二容器部分的子区域和第一容器部分的子区域重叠。
    • 7. 发明授权
    • Polymeric delivery formulations of leuprolide with improved efficacy
    • 亮丙瑞林的聚合物制剂具有改善的功效
    • EP2158900B1
    • 2013-01-23
    • EP09012462.9
    • 2001-09-21
    • QLT USA, Inc.
    • Dunn, Richard L.Garrett, John S.Ravivarapu, HarishChandrashekar, Bhagya L.
    • A61K9/00A61K38/09A61K47/34
    • A61K38/09A61K9/0019A61K9/0024A61K9/19A61K47/22A61K47/34B65D81/3205
    • The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. The present invention is also directed to a method for forming the flowable composition. The present invention is also directed to a biodegradable implant formed in situ, in a patient. The biodegradable implant is formed by injecting a flowable composition within the body of the patient and allowing the biocompatible polar aprotic solvent to dissipate to produce a solid biodegradable implant. The present invention is also directed to a method of forming a biodegradable implant in situ, in a living patient. The method includes injecting a flowable composition within the body of a patient and allowing the biocompatible polar aprotic solvent to dissipate to produce a solid biodegradable implant. The present invention is also directed to a method of treating cancer in a patient. The method includes administering to the patient in need of such treatment an effective amount of a flowable composition of the present invention. The present invention is also directed to a method of reducing LHRH levels in a patient. The method includes administering to the patient in need of such LHRH reduction an effective amount of a flowable composition of the present invention. The present invention is also directed to a kit. The kit includes a first container and a second container. The first container includes a composition that includes a biodegradable thermoplastic polyester and a biocompatible polar aprotic solvent. The second container includes leuprolide acetate. The present invention is also directed to a solid implant. The solid implant includes a biocompatible thermoplastic polyester and leuprolide acetate. The solid implant has a solid or gelatinous microporous matrix, wherein the matrix is a core surrounded by a skin. The solid implant can further include a biocompatible organic solvent.